A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

About this Attention Score

• In the top 5% of all research outputs scored by Altmetric
• Among the highest-scoring outputs from this source (#36 of 222)
• High Attention Score compared to outputs of the same age (95th percentile)
• Average Attention Score compared to outputs of the same age and source